United States

Axovant Gene Therapies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Axovant Announces Upcoming Presentations at the Annual Meeting of the American Society of Gene and Cell Therapy

Lead Product(s): rAAVrh8-HexA/HexB

Therapeutic Area: Genetic Disease

Highest Development Status: Undisclosed Product Type: Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 07, 2020

Details:

Presentations to showcase Axovant's investigational gene therapy programs, AXO-Lenti-PD and AXO-AAV-GM2.

Affinia Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Vertex Pharmaceuticals and Affinia Therapeutics Set Up Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies

Lead Product(s): AAV capsid-gene therapy

Therapeutic Area: Genetic Disease

Highest Development Status: Undisclosed Product Type: Gene therapy

Partner/Sponsor/Collaborator: Vertex Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 27, 2020

Details:

Affinia Therapeutics’ proprietary AAV vector technology to be used in Vertex’s genetic therapy efforts with focus on Duchenne muscular dystrophy, myotonic dystrophy type 1 and cystic fibrosis.

Myosana Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Myosana Therapeutics, Inc. Raises Up To $1M from CureDuchenne Ventures

Lead Product(s): Non-viral gene therapy

Therapeutic Area: Genetic Disease

Highest Development Status: Undisclosed Product Type: Gene therapy

Partner/Sponsor/Collaborator: CureDuchenne Ventures

Deal Size: $1.0 million Upfront Cash: Undisclosed

Deal Type: Financing April 22, 2020

Details:

Myosana will use this initial funding to advance development of its innovative non-viral gene therapy to deliver full length dystrophin for Duchenne muscular dystrophy (DMD).

Dyne Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Dyne Therapeutics Announces Equity Investment from CureDuchenne Ventures

Lead Product(s): Oligonucleotide linked antibody

Therapeutic Area: Genetic Disease

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: CureDuchenne Ventures

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Financing March 31, 2020

Details:

The funding will support Dyne’s development of precision therapeutics designed to restore muscle health in people living with Duchenne muscular dystrophy (DMD).

ReCode Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

ReCode Therapeutics Raises $80 Million in Oversubscribed Series A Financing

Lead Product(s): mRNA-mediated protein replacement therapies

Therapeutic Area: Genetic Disease

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: MPM Capital

Deal Size: $80.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing March 26, 2020

Details:

ReCode will use the proceeds to continue the preclinical development of its lead programs in primary ciliary dyskinesia and cystic fibrosis.

Vigene Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

ASC Therapeutics and Vigene Announce Long-Term Strategic Partnership for Gene Therapy Development and Manufacturing

Lead Product(s): Viral vector gene therapy

Therapeutic Area: Genetic Disease

Highest Development Status: Undisclosed Product Type: Gene therapy

Partner/Sponsor/Collaborator: ASC Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership January 14, 2020

Details:

Vigene will provide ASC with access to GMP mfg including viral vectors and plasmid DNA for its Hemophilia A gene therapy clinical program, as well as a manufacturing platform for future programs.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

Axovant Gene Therapies

Axovant Announces Upcoming Presentations at the Annual Meeting of the American Society of Gene and Cell Therapy

Affinia Therapeutics

Vertex Pharmaceuticals and Affinia Therapeutics Set Up Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies

Myosana Therapeutics

Myosana Therapeutics, Inc. Raises Up To $1M from CureDuchenne Ventures

Dyne Therapeutics

Dyne Therapeutics Announces Equity Investment from CureDuchenne Ventures

ReCode Therapeutics

ReCode Therapeutics Raises $80 Million in Oversubscribed Series A Financing

Vigene Bioscience

ASC Therapeutics and Vigene Announce Long-Term Strategic Partnership for Gene Therapy Development and Manufacturing